[go: up one dir, main page]

WO2011041731A3 - Procédé destiné à inhiber des protéines de survie apparentées aux bcl-2 - Google Patents

Procédé destiné à inhiber des protéines de survie apparentées aux bcl-2 Download PDF

Info

Publication number
WO2011041731A3
WO2011041731A3 PCT/US2010/051201 US2010051201W WO2011041731A3 WO 2011041731 A3 WO2011041731 A3 WO 2011041731A3 US 2010051201 W US2010051201 W US 2010051201W WO 2011041731 A3 WO2011041731 A3 WO 2011041731A3
Authority
WO
WIPO (PCT)
Prior art keywords
survival proteins
inhibiting bcl
related survival
subject
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/051201
Other languages
English (en)
Other versions
WO2011041731A2 (fr
Inventor
David Hockenbery
Julian Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of WO2011041731A2 publication Critical patent/WO2011041731A2/fr
Publication of WO2011041731A3 publication Critical patent/WO2011041731A3/fr
Priority to US13/437,795 priority Critical patent/US8865901B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement d'une maladie associée à l'apoptose chez un sujet le nécessitant, qui consiste à administrer à ce sujet une quantité thérapeutiquement efficace d'un composé actif qui est particulièrement cytotoxique contre des cellules tumorales qui surexpriment les Bcl-xL, et qui sont bien moins cytotoxiques envers les cellules isogéniques qui ne surexpriment pas les Bcl-XL. L'invention concerne également plusieurs échafaudages de composés actifs.
PCT/US2010/051201 2009-10-02 2010-10-01 Procédé destiné à inhiber des protéines de survie apparentées aux bcl-2 Ceased WO2011041731A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/437,795 US8865901B2 (en) 2009-10-02 2012-04-02 Gain-of-function Bcl-2 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24829609P 2009-10-02 2009-10-02
US61/248,296 2009-10-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051208 Continuation-In-Part WO2011041737A2 (fr) 2009-10-02 2010-10-01 Inhibiteurs de bcl-2 à gain de fonction

Publications (2)

Publication Number Publication Date
WO2011041731A2 WO2011041731A2 (fr) 2011-04-07
WO2011041731A3 true WO2011041731A3 (fr) 2011-06-16

Family

ID=43304767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051201 Ceased WO2011041731A2 (fr) 2009-10-02 2010-10-01 Procédé destiné à inhiber des protéines de survie apparentées aux bcl-2

Country Status (1)

Country Link
WO (1) WO2011041731A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865901B2 (en) 2009-10-02 2014-10-21 Fred Hutchinson Cancer Research Center Gain-of-function Bcl-2 inhibitors
US9603844B2 (en) * 2012-10-22 2017-03-28 Georgetown University Compositions and methods for treating mammary tumors
KR102027532B1 (ko) * 2017-11-13 2019-10-01 연세대학교 원주산학협력단 메틸렌비스 및 관련 화합물의 자가포식 조절 기전을 이용하여 dna 토포이소머라제1 억제제의 항암 효능 증진 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084647A1 (en) * 2004-08-20 2006-04-20 Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
US20060094059A1 (en) * 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
WO2008133884A2 (fr) * 2007-04-23 2008-11-06 Combinatorx, Incorporated Procédés et compositions pour traiter des maladies neurodégénératives
WO2009008906A2 (fr) * 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Composés thérapeutiques pour un blocage de la synthèse d'adn de poxvirus
WO2009023299A2 (fr) * 2007-04-13 2009-02-19 Southern Research Institute Agents anti-angiogéniques et procédés d'utilisation
US20090192220A1 (en) * 2007-11-19 2009-07-30 Ore Pharmaceuticals Inc. Treatment for solid tumors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
CA2170874A1 (fr) 1993-09-30 1995-04-06 Minoru Okada Derive d'azole et composition pharmaceutique le contenant
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6004617A (en) 1994-10-18 1999-12-21 The Regents Of The University Of California Combinatorial synthesis of novel materials
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
US6077954A (en) 1996-08-01 2000-06-20 Isis Pharmaceuticals, Inc. Substituted heterocyclic compounds
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
EP1019034A2 (fr) 1997-07-01 2000-07-19 Atherogenics, Inc. Amelioration au moyen d'antioxydants de la therapie destinee aux etats d'hyperproliferation
US5848379A (en) 1997-07-11 1998-12-08 Exxon Production Research Company Method for characterizing subsurface petrophysical properties using linear shape attributes
US20050239873A1 (en) 1999-08-20 2005-10-27 Fred Hutchinson Cancer Research Center 2 Methoxy antimycin a derivatives and methods of use
JP2001078776A (ja) 1999-09-14 2001-03-27 Inst Of Physical & Chemical Res Ｎａｄｅ結合蛋白質
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6632616B2 (en) 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
US7241804B1 (en) 2000-08-18 2007-07-10 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
WO2005033048A2 (fr) 2003-09-29 2005-04-14 The Johns Hopkins University Antagonistes de voie wnt
WO2008021250A2 (fr) 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions et procédés de modulation de l'apoptose dans des cellules surexprimant des protéines membres de la famille bcl-2
WO2008021211A2 (fr) 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions et procédés de modulation de l'apoptose dans des cellules surexprimant les protéines membres de la famille bcl-2

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084647A1 (en) * 2004-08-20 2006-04-20 Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
US20060094059A1 (en) * 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
WO2009008906A2 (fr) * 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Composés thérapeutiques pour un blocage de la synthèse d'adn de poxvirus
WO2009023299A2 (fr) * 2007-04-13 2009-02-19 Southern Research Institute Agents anti-angiogéniques et procédés d'utilisation
WO2008133884A2 (fr) * 2007-04-23 2008-11-06 Combinatorx, Incorporated Procédés et compositions pour traiter des maladies neurodégénératives
US20090192220A1 (en) * 2007-11-19 2009-07-30 Ore Pharmaceuticals Inc. Treatment for solid tumors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARELIER SARAH ET AL: "Fragment-based deconstruction of Bcl-xL inhibitors.", JOURNAL OF MEDICINAL CHEMISTRY 25 MAR 2010 LNKD- PUBMED:20192224, vol. 53, no. 6, 25 March 2010 (2010-03-25), pages 2577 - 2588, XP002614929, ISSN: 1520-4804 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1974, PLISS, G. B. ET AL: "Inhibition of O- aminoazotoluene -induced tumors by antioxidants", XP002614928, retrieved from STN Database accession no. 1975:38563 *
DEYE J ET AL: "Structure-based virtual screening for novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase and their experimental evaluation", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 17, no. 3, 1 February 2009 (2009-02-01), pages 1353 - 1360, XP025925762, ISSN: 0968-0896, [retrieved on 20081214], DOI: DOI:10.1016/J.BMC.2008.12.010 *
VOPROSY ONKOLOGII, vol. 20, no. 7, 1974, pages 47 - 49 *

Also Published As

Publication number Publication date
WO2011041731A2 (fr) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2010068810A3 (fr) Amides substitués, et leurs procédés de production et d'utilisation
WO2011099832A3 (fr) Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
WO2011055944A3 (fr) Procédés pour traiter un syndrome de fibromyalgie
IL245290A0 (en) A medical system for introducing the active substance buprenorphine through the skin
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
IL210813A0 (en) Methods of administering topical antifungal formulations for the treatment of fungal infections
WO2012064897A3 (fr) Inhibiteurs bicyliques et tricycliques d'enzymes de sumoylation et leurs procédés d'utilisation
WO2012002687A3 (fr) Procédés de traitement du trouble bipolaire
WO2011156811A3 (fr) Composés pour le traitement de la mastite bovine
WO2010107807A3 (fr) Composés destinés au traitement de l'inflammation et de la douleur
MX2009009574A (es) Tratamiento de melanoma.
WO2010098600A3 (fr) Dérivés d'azole substitués, composition pharmaceutique contenant les dérivés et procédé de traitement de la maladie de parkinson à l'aide de ceux-ci
WO2008147483A3 (fr) Composés neurogéniques
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2011041731A3 (fr) Procédé destiné à inhiber des protéines de survie apparentées aux bcl-2
WO2010039920A3 (fr) Composés à base de boldine pour favoriser la croissance osseuse
WO2009155070A3 (fr) Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques
WO2012103282A3 (fr) Procédés et compositions convenant au traitement de la maladie d'alzheimer
WO2006081445A3 (fr) Traitement de tumeurs metastatiques
WO2009088992A3 (fr) Composés à base de ribonucléase et de thiazolidinedione et leur utilisation dans des procédés de traitement du cancer
WO2008036733A3 (fr) Méthodes de traitement de troubles du transport vésiculaire
WO2012153253A3 (fr) Composés aromatiques et complexes métalliques de ceux-ci
WO2007014253A3 (fr) Methode permettant de traiter ou de prevenir la deterioration, les lesions ou les dommages tissulaires causes par l'insuffisance cardiaque congestive

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762846

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762846

Country of ref document: EP

Kind code of ref document: A2